For the Inventor, By the Inventor

Enter assignee name

Meiji Seika Pharma Co., Ltd.

USPTO Granted Patents = 107

CIPO Patents = 19

EPO Patents = 86

Trademarks = 9

Forward Citations = 317

Loading Chart...

Loading Chart...

188 inventors (with patents filed for the assignee):

Takao Abe (18 out of 84 patents)

Masaaki Mitomi (18 out of 26 patents)

Yoshiaki Sakamaki (17 out of 17 patents)

4. Takeshi Furuuchi (13 out of 13 patents)

5. Ryo Horikoshi (13 out of 21 patents)

6. Nozomu Nakanishi (11 out of 15 patents)

7. Nobuto Minowa (11 out of 24 patents)

8. Shigeki Kitsuda (8 out of 8 patents)

9. Fumikazu Yokoyama (8 out of 9 patents)

10. Koji Yanai (8 out of 18 patents)

11. Kazuhiko Oyama (8 out of 14 patents)

12. Yasumichi Onozaki (7 out of 10 patents)

13. Masahiro Nomura (7 out of 9 patents)

14. Kaoru Okakura (7 out of 12 patents)

15. Kimihiko Goto (7 out of 10 patents)

Core Competencies:

Mesostigmata Mite Control

Diazabicyclooctane Derivative

Aminoglycoside Antibiotic

Pest Control Composition

Crystalline Forms

Beta-Lactamase Inhibitor

Pharmaceutical for Dysphagia

Mutant Xylanase

Sphingosine-1-Phosphate Agonists

Therapeutic Agents

Crystalline Anti-Trichophyton Agents

Cellulase Gene

107 patents: Sort by Forward Citations

1. 12419306 - Mesostigmata mite control composition (2025-09-23),

2. 12239643 - Therapeutic agent for inflammatory diseases, autoimmune diseases, fibrotic diseases, and cancer diseases (2025-03-04),

3. 12221443 - Crystalline forms of diazabicyclooctane derivative and production process thereof (2025-02-11),

4. 12108761 - Mesostigmata mite control agent (2024-10-08),

5. 12103928 - Processes for preparing a diazabicyclooctane compound (2024-10-01),

6. 11731971 - Processes for preparing a diazabicyclooctane compound (2023-08-22),

7. 11512091 - Crystal of benzoxazole derivative (2022-11-29),

8. 11414417 - Crystalline forms of diazabicyclooctane derivative and production process thereof (2022-08-16),

9. 11267787 - Method for producing quinolin-4(1H)-one derivative (2022-03-08),

10. 11135234 - Effective aminoglycoside antibiotic for multidrug-resistant bacteria (2021-10-05),

11. 11117896 - Processes for preparing a diazabicyclooctane compound (2021-09-14),

12. 11117895 - Process for producing crystals of a diazabicyclooctane derivative (2021-09-14),

13. 10774318 - Cellulase gene (2020-09-15),

14. 10759800 - Crystalline forms of diazabicyclooctane derivatives and production process thereof (2020-09-01),

15. 10736319 - Pest control composition including novel iminopyridine derivative (2020-08-11),

Meiji Seika Pharma Co., Ltd. is a pharmaceutical company based in Japan. It is primarily engaged in the research, development, manufacturing, and marketing of pharmaceutical products. The company provides a wide range of prescription drugs, over-the-counter medications, and healthcare products. Meiji Seika Pharma aims to contribute to the well-being of people by continuously pursuing innovation in pharmaceuticals and improving the quality of life.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

107 Patents

#456 in Tokyo

#1,053 in Japan

#7,129 in the World

Meiji Seika Pharma Co., Ltd.

Forward Citations = 317

188 inventors:

Takao Abe (18 out of 84 patents)

Masaaki Mitomi (18 out of 26 patents)

Yoshiaki Sakamaki (17 out of 17 patents)

4. Takeshi Furuuchi (13 out of 13 patents)

5. Ryo Horikoshi (13 out of 21 patents)

Please report any incorrect information to support@idiyas.com

Loading…